Yoshinori Fukazawa

Yoshinori Fukazawa

Auto-generated profile, based on publicly available information

Yoshinori Fukazawa

Vaccine and Gene Therapy Institute and

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AOAfam A. Okoye
Afam A. Okoye
DDDerick D. Duell
Derick D. Duell
YFYoshinori Fukazawa
Yoshinori Fukazawa
BVBenjamin Varco-Merth
Benjamin Varco-Merth
AMAlejandra Marenco
Alejandra Marenco
LPLouis J. Picker
Louis J. Picker
To define the contribution of CD8+ T cell responses to control of SIV reactivation during and following antiretroviral therapy (ART), we determined the effect of long-term CD8+ T cell depletion using a rhesusized anti-CD8β monoclonal antibody on barcoded SIVmac239 dynamics on stable ART and after ART cessation in rhesus macaques (RMs). Among the RMs with full CD8+ T cell depletion in both blood and tissue, there were no significant differences in the frequency of viral blips in plasma, the number of SIV RNA+ cells and the average number of RNA copies/infected cell in tissue, and levels of cell-associated SIV RNA and DNA in blood and tissue relative to control-treated RMs during ART. Upon ART cessation, both CD8+ T cell–depleted and control RMs rebounded in fewer than 12 days, with no difference in the time to viral rebound or in either the number or growth rate of rebounding SIVmac239M barcode clonotypes. However, effectively CD8+ T cell–depleted RMs showed a stable, approximately 2-log increase in post-ART plasma viremia relative to controls. These results indicate that while potent antiviral CD8+ T cell responses can develop during ART-suppressed SIV infection, these responses effectively intercept post-ART SIV rebound only after systemic viral replication, too late to limit reactivation frequency or the early spread of reactivating SIV reservoirs.

1 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KEKarsten Eichholz
Karsten Eichholz
YFYoshinori Fukazawa
Yoshinori Fukazawa
CPChristopher W. Peterson
Christopher W. Peterson
FHFrancoise Haeseleer
Francoise Haeseleer
MMManuel Medina
Manuel Medina
LCLawrence Corey
Lawrence Corey
Programmed cell death protein 1 (PD-1) is an immune checkpoint marker commonly expressed on memory T cells and enriched in latently HIV-infected CD4 + T cells. We engineered an anti–PD-1 chimeric antigen receptor (CAR) to assess the impact of PD-1 depletion on viral reservoirs and rebound dynamics in SIVmac239–infected rhesus macaques (RMs). Adoptive transfer of anti–PD-1 CAR T cells was done in 2 SIV-naive and 4 SIV-infected RMs on antiretroviral therapy (ART). In 3 of 6 RMs, anti–PD-1 CAR T cells expanded and persisted for up to 100 days concomitant with the depletion of PD-1 + memory T cells in blood and tissues, including lymph node CD4 + follicular helper T (TFH) cells. Loss of TFH cells was associated with depletion of detectable SIV RNA from the germinal center (GC). However, following CAR T infusion and ART interruption, there was a marked increase in SIV replication in extrafollicular portions of lymph nodes, a 2-log higher plasma viremia relative to controls, and accelerated disease progression associated with the depletion of CD8 + memory T cells. These data indicate anti–PD-1 CAR T cells depleted PD-1 + T cells, including GC TFH cells, and eradicated SIV from this immunological sanctuary.

16 May 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BVBenjamin D. Varco-Merth
Benjamin D. Varco-Merth
WBWilliam Brantley
William Brantley
AMAlejandra Marenco
Alejandra Marenco
DDDerick D. Duell
Derick D. Duell
DFDevin Fachko
Devin Fachko
AOAfam A. Okoye
Afam A. Okoye
Proliferation of latently infected CD4+ T cells with replication-competent proviruses is an important mechanism contributing to HIV persistence during antiretroviral therapy (ART). One approach to targeting this latent cell expansion is to inhibit mTOR, a regulatory kinase involved with cell growth, metabolism, and proliferation. Here, we determined the effects of chronic mTOR inhibition with rapamycin with or without T cell activation in SIV-infected rhesus macaques (RMs) on ART. Rapamycin perturbed the expression of multiple genes and signaling pathways important for cellular proliferation and substantially decreased the frequency of proliferating CD4+ memory T cells (TM cells) in blood and tissues. However, levels of cell-associated SIV DNA and SIV RNA were not markedly different between rapamycin-treated RMs and controls during ART. T cell activation with an anti-CD3LALA antibody induced increases in SIV RNA in plasma of RMs on rapamycin, consistent with SIV production. However, upon ART cessation, both rapamycin and CD3LALA–treated and control-treated RMs rebounded in less than 12 days, with no difference in the time to viral rebound or post-ART viral load set points. These results indicate that, while rapamycin can decrease the proliferation of CD4+ TM cells, chronic mTOR inhibition alone or in combination with T cell activation was not sufficient to disrupt the stability of the SIV reservoir.

18 January 2022 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
AOAfam A. Okoye
Afam A. Okoye
RFRémi Fromentin
Rémi Fromentin
HTHiroshi Takata
Hiroshi Takata
JBJessica H. Brehm
Jessica H. Brehm
YFYoshinori Fukazawa
Yoshinori Fukazawa
NCNicolas Chomont
Nicolas Chomont
Activation of the NF-κB signaling pathway by Protein Kinase C (PKC) agonists is a potent mechanism for human immunodeficiency virus (HIV) latency disruption in vitro. However, significant toxicity risks and the lack of evidence supporting their activity in vivo have limited further evaluation of PKC agonists as HIV latency-reversing agents (LRA) in cure strategies. Here we evaluated whether GSK445A, a stabilized ingenol-B derivative, can induce HIV/simian immunodeficiency virus (SIV) transcription and virus production in vitro and demonstrate pharmacological activity in nonhuman primates (NHP). CD4+ T cells from people living with HIV and from SIV+ rhesus macaques (RM) on antiretroviral therapy (ART) exposed in vitro to 25 nM of GSK445A produced cell-associated viral transcripts as well as viral particles at levels similar to those induced by PMA/Ionomycin, indicating that GSK445A can potently reverse HIV/SIV latency. Importantly, these concentrations of GSK445A did not impair the proliferation or survival of HIV-specific CD8+ T cells, but instead, increased their numbers and enhanced IFN-γ production in response to HIV peptides. In vivo, GSK445A tolerability was established in SIV-naïve RM at 15 μg/kg although tolerability was reduced in SIV-infected RM on ART. Increases in plasma viremia following GSK445A administration were suggestive of increased SIV transcription in vivo. Collectively, these results indicate that GSK445A is a potent HIV/SIV LRA in vitro and has a tolerable safety profile amenable for further evaluation in vivo in NHP models of HIV cure/remission.

4 November 2009 in Journal of General Virology
Verified
Journal Article
Open access
KIKatsuhisa Inaba
Katsuhisa Inaba
YFYoshinori Fukazawa
Yoshinori Fukazawa
KMKenta Matsuda
Kenta Matsuda
AHA. Himeno
A. Himeno
MMMegumi Matsuyama
Megumi Matsuyama
TMTomoyuki Miura
Tomoyuki Miura
Human immunodeficiency virus type 1, simian immunodeficiency virus and simian/human immunodeficiency virus (SHIV) infection generally lead to death of the host accompanied by high viraemia and profound CD4+ T-cell depletion. SHIV clone KS661-infected rhesus macaques with a high viral load set point (HVL) ultimately experience diarrhoea and wasting at 6–12 months after infection. In contrast, infected macaques with a low viral load set point (LVL) usually live asymptomatically throughout the observation period, and are therefore referred to as asymptomatic LVL (Asym LVL) macaques. Interestingly, some LVL macaques exhibit diarrhoea and wasting similar to the symptoms of HVL macaques and are termed symptomatic LVL (Sym LVL) macaques. This study tested the hypothesis that Sym LVL macaques have the same degree of intestinal abnormalities as HVL macaques. The proviral DNA loads in lymphoid tissue and the intestines of Sym LVL and Asym LVL macaques were comparable and all infected monkeys showed villous atrophy. Notably, the CD4+ cell frequencies of lymphoid tissues and intestines in Sym LVL macaques were remarkably lower than those in Asym LVL and uninfected macaques. Furthermore, Sym LVL and HVL macaques exhibited an increased number of activated macrophages. In conclusion, intestinal disorders including CD4+ cell reduction and abnormal immune activation can be observed in SHIV-KS661-infected macaques independent of virus replication levels.

1 January 2012 in Uirusu
Verified
Journal Article
Open access
PDF file
YFYoshinori Fukazawa
Yoshinori Fukazawa
サル免疫不全ウイルス(SIV)を用いたサルエイズモデルにおいて,弱毒SIV生ワクチンは,他のワクチンよりも強毒SIV攻撃接種に対し高い防御効果を示すが,その防御機序はいまだ解明されていない.筆者らによる最近の弱毒SIV生ワクチン免疫相関研究において,その防御効果は,抹消血,粘膜組織のSIV特異的T細胞免疫反応および血漿中抗体価とは相関しなかったが,リンパ節のSIV特異的CD4+およびCD8+T細胞免疫反応とは相関が認められた.この防御効果を示したサル個体群では,弱毒生ワクチン株がリンパ節濾胞性CD4+T細胞において持続感染することにより,高頻度のエフェクターメモリーT細胞免疫反応が誘導・維持されていた.よって,弱毒SIV生ワクチンによる防御免疫は,2次リンパ組織における持続的な抗原産生により誘導されるエフェクターメモリーT細胞免疫反応によるものと考えられる.本稿では,この最新の知見から弱毒SIV生ワクチンによる防御免疫誘導のメカニズムを解説し,有効なエイズワクチンに重要な免疫反応について言及したい.